The best indicator for Bunge Global (BG)
We backtested 20 indicators across daily, weekly and hourly charts on real Bunge Global (BG) history. Here's what actually worked — risk-adjusted, out-of-sample, with costs.
MACD
On the weekly chart, this is the strongest risk-adjusted edge we found for Bunge Global (BG) over ~24.9 years — trailing buy-and-hold by 1.7% CAGR.
The winner on each chart
Every indicator, ranked
Ranked by Sharpe (risk-adjusted return). Hypothetical, fees included.
| # | Indicator | TF | CAGR | Sharpe | Max DD | Win | Trades | vs B&H |
|---|---|---|---|---|---|---|---|---|
| 1 | MACD ✓ | Weekly | 9.1% | 0.52 | -33.9% | 58.1% | 43 | -1.7% |
| 2 | WaveTrend (8/6/4) ✓ | Weekly | 7.5% | 0.46 | -62.9% | 78.3% | 23 | -3.3% |
| 3 | SMA 50/200 Cross ✓ | Daily | 6.7% | 0.4 | -51.6% | 47.8% | 23 | -4.2% |
| 4 | Williams %R ✓ | Daily | 6.7% | 0.4 | -73.2% | 68.7% | 163 | -4.2% |
| 5 | EMA-10 Trend ✓ | Weekly | 6.6% | 0.4 | -47.7% | 47.9% | 119 | -4.2% |
| 6 | Bollinger Mean-Reversion ✓ | Weekly | 5.2% | 0.39 | -38.3% | 71.4% | 21 | -5.7% |
| 7 | RSI Trend (>50) ✓ | Weekly | 6.1% | 0.38 | -51.5% | 44.6% | 74 | -4.7% |
| 8 | Donchian Midline ✓ | Weekly | 6.1% | 0.38 | -46.0% | 48.4% | 64 | -4.8% |
| 9 | Bollinger Breakout ✓ | Weekly | 4.2% | 0.35 | -34.6% | 47.8% | 23 | -6.6% |
| 10 | EMA 50/200 Cross ✓ | Daily | 5.2% | 0.34 | -64.6% | 26.1% | 23 | -5.8% |
| 11 | EMA 20/50 Cross ✓ | Weekly | 5.6% | 0.36 | -59.3% | 35.7% | 14 | -5.3% |
| 12 | Heikin-Ashi Trend ✓ | Weekly | 5.1% | 0.33 | -50.5% | 51.5% | 237 | -5.8% |
| 13 | WaveTrend (8/6/4) ✓ | Daily | 4.5% | 0.31 | -73.9% | 65.2% | 92 | -6.4% |
| 14 | Donchian Breakout ✓ | Weekly | 4.2% | 0.31 | -54.4% | 45.5% | 22 | -6.7% |
✓ = held up out-of-sample. Hypothetical, costs included. See methodology.
For Bunge Global (BG), MACD on the weekly timeframe gave the best balance of return and risk in our test. It still trailed buy-and-hold on raw return — but remember: this is a hypothetical backtest of a standard rule, not a recommendation. Markets change. See the methodology and disclaimer.
More stock
Get the weekly edge report
The best-performing indicator per asset, what changed this week, and the honest caveats — straight to your inbox.